ESC

ESC 2022: surgical risk guideline points to perioperative cardiovascular complications

ESC 2022: surgical risk guideline points to perioperative cardiovascular complications

Patients undergoing non-cardiac surgery may have some cardiovascular complications, the most common being perioperative myocardial infarction/injury (MI). This complication is asymptomatic in up to 90% of patients and underdiagnosed if not actively investigated. This occurs because patients are usually under the effect of anesthesia or potent analgesia. In addition, symptoms are often confused with symptoms …

ESC 2022: surgical risk guideline points to perioperative cardiovascular complications Read More »

ESC 2022: Guideline guides on cardiovascular surgical risk assessments and which additional tests to perform

ESC 2022: Guideline guides on cardiovascular surgical risk assessments and which additional tests to perform

The majority of surgeries performed today are non-cardiac surgeries, and with the changing demographics of the population, we are increasingly operating on older patients with more cardiovascular risk factors or established disease. Perioperative cardiovascular complications usually occur as a result of hemodynamic and cardiac stress to which patients are subjected and are more frequent in …

ESC 2022: Guideline guides on cardiovascular surgical risk assessments and which additional tests to perform Read More »

ESC 2022: Guideline provides surgical risk reduction guidelines to be passed on to the patient in the preoperative evaluation

ESC 2022: Guideline provides surgical risk reduction guidelines to be passed on to the patient in the preoperative evaluation

During the congress of European Society of Cardiology (ESC 2022), the guideline for preoperative assessments was presented, which brought, among other matters, guidelines to be passed on to the patient to reduce surgical risk.urgic. They concern the consumption of tobacco and the use of medication. See below what the guideline points out. Read too: New …

ESC 2022: Guideline provides surgical risk reduction guidelines to be passed on to the patient in the preoperative evaluation Read More »

ESC 2022: Is DAPT use safe for patients at high risk of bleeding after angioplasty?

ESC 2022: Is DAPT use safe for patients at high risk of bleeding after angioplasty?

In the MASTER DAPT study, patients with acute or chronic coronary heart disease and high risk of bleeding who underwent angioplasty with stents Drugs were randomized after one month of dual antiplatelet therapy (DAPT) for the usual time or treatment with monotherapy from that first month. Follow the full coverage of ESC 2022 Study characteristics …

ESC 2022: Is DAPT use safe for patients at high risk of bleeding after angioplasty? Read More »

ESC 2022: Drug treatment and PCI for CAD and technological innovations at ECO

ESC 2022: New directions for cardiology with artificial intelligence

PEBMED, with the support of Pfizer, will bring exclusive content about the European Society of Cardiology (ESC) 2022, which takes place from August 26 to 29, in Barcelona. Check now the new directions of cardiology with artificial intelligence. Follow the full coverage of the congress Technologies are increasingly present in medicine and in the routine …

ESC 2022: New directions for cardiology with artificial intelligence Read More »

ESC 2022: Drug treatment and PCI for CAD and technological innovations at ECO

ESC 2022: What is the dose-response relationship of milvexian in patients with ischemic stroke or TIA?

The risk of stroke recurrence in patients with previous stroke or TIA reaches 10% in the first months and the attempt to reduce this risk has been with the use of antiplatelet drugs. New strategies have shown improvement in outcomes, but there is still a residual risk and increased risk of bleeding with the use …

ESC 2022: What is the dose-response relationship of milvexian in patients with ischemic stroke or TIA? Read More »

ESC 2022: What is the best dosage of asundexian in post-acute myocardial infarction?

ESC 2022: What is the best dosage of asundexian in post-acute myocardial infarction?

In post-acute myocardial infarction, antiplatelet therapy with aspirin and a P2Y12 inhibitor is effective in reducing new thrombotic events, but at the expense of increased bleeding. The use of warfarin or rivaroxaban also reduces ischemic events, but the risk of bleeding becomes high with this triple association. Asundexian is a factor inhibitor XIa with the …

ESC 2022: What is the best dosage of asundexian in post-acute myocardial infarction? Read More »

ESC 2022: Drug treatment and PCI for CAD and technological innovations at ECO

ESC 2022: Drug treatment and PCI for CAD and technological innovations at ECO

PEBMED, with the support of Pfizer, will bring exclusive content about the European Society of Cardiology (ESC) 2022, which takes place from August 26 to 29, in Barcelona. Check out the approaches for drug and interventional treatment of myocardial ischemia disease and technological innovations in echocardiography: Chronic coronary syndrome is the most prevalent heart disease …

ESC 2022: Drug treatment and PCI for CAD and technological innovations at ECO Read More »

ESC 2022: Diretriz cardio-oncologia

ESC 2022: What is the result of the 5-year cardiovascular disease screening study?

Cardiovascular diseases are the leading cause of death in the world and in Europe it represents 45% of deaths in women and 39% in men and is the main cause of early death in men, reaching 33% of causes in men under 70 years of age. Also read: ESC 2022: ADVOR Study A randomized study …

ESC 2022: What is the result of the 5-year cardiovascular disease screening study? Read More »

ESC 2022: Diretriz cardio-oncologia

ESC 2022: ADVOR study evaluates the use of acetazolamide to improve congestion in patients with HF

The ADVOR study, presented at the European Congress (ESC 2022), aimed to assess whether the use of acetazolamide associated with standard therapy with intravenous loop diuretics would lead to greater success in improving congestion in patients with heart failure (HF). Read too: ESC 2022: Cardio-oncology Guideline It was a multicenter, randomized, placebo-controlled, double-blind study that …

ESC 2022: ADVOR study evaluates the use of acetazolamide to improve congestion in patients with HF Read More »